Subtype
Uterine Corpus Neoplasm
CI-CAN-00007035Explore in graph →
Non-malignant451 active trials4 approved drugs28 evidence items
- NCIt
- C6300
Loading cancer entity…
Subtype
CI-CAN-00007035Explore in graph →
Clinical trials
1,714 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00381888 | Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer | completed | Phase 2 | 44 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 28, 2017 | clinicaltrials |
| NCT00610740 | CerviPrep for Applying Topical Gemcitabine to the Cervix in Treating Patients With Primary Endometrial, Cervical, or Ovarian Epithelial Cancer | completed | Phase 2 | 18 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 28, 2017 |
| clinicaltrials |
| NCT00888173 | Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer | completed | Phase 2 | 45 | Gynecologic Oncology GroupNETWORK | 1 | Dec 6, 2017 | clinicaltrials |
| NCT01225887 | Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer | completed | Phase 2 | 37 | Gynecologic Oncology GroupNETWORK | 1 | Oct 9, 2017 | clinicaltrials |
| NCT00039442 | Capecitabine in Treating Patients With Persistent or Recurrent Cervical Cancer | completed | Phase 2 | 21 | Gynecologic Oncology GroupNETWORK | 1 | Aug 24, 2017 | clinicaltrials |
| NCT00332033 | Development of a Non-Invasive Treatment for Uterine Leiomyoma (Fibroids) | completed | Phase 2 | 32 | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NIH | 1 | Jul 2, 2017 | clinicaltrials |
| NCT02684318 | Study to Evaluate PM01183 in Combination With Olaparib in Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 100 | Poveda, Andrés, M.D.INDIV | 1 | Jun 22, 2017 | clinicaltrials |
| NCT01184053 | Trisenox® in Women With Metastatic Endometrial Cancer(NRR) | terminated | Phase 2 | 3 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jun 14, 2017 | clinicaltrials |
| NCT01461746 | Efficacy Study of Chemotherapy Followed by Radiation Therapy to Treat Endometrial Cancer | unknown | Phase 2 | 67 | Asan Medical CenterOTHER | 1 | May 31, 2017 | clinicaltrials |
| NCT01461759 | Efficacy Study of Chemotherapy to Treat Advanced or Recurrent Endometrial Cancer | unknown | Phase 2 | 59 | Asan Medical CenterOTHER | 1 | May 31, 2017 | clinicaltrials |
| NCT00879359 | Trial of Vascular Endothelial Growth Factor (VEGF), Bevacizumab, in Combination With Cytotoxic Chemotherapy for Endometrial Cancer | completed | Phase 2 | 15 | The Cleveland ClinicOTHER | 1 | Apr 26, 2017 | clinicaltrials |
| NCT01504308 | Sonalleve Fibroid Ablation Pivotal Clinical Trial for MR-HIFU of Uterine Fibroids(SOFIA) | terminated | Phase 2 / Phase 3 | 49 | Philips HealthcareINDUSTRY | 3 | Apr 5, 2017 | clinicaltrials |
| NCT00545792 | Safety Study Of Avastin And Pelvic Radiation In Women With Recurrent Gynecological Cancers | completed | Phase 2 | 21 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 15, 2017 | clinicaltrials |
| NCT02064725 | Virexxa (Sodium Cridanimod) w/Progestin Therapy in Pts w/Progesterone Receptor Neg Recurrent/Persistent Endometrial CA | unknown | Phase 2 | 8 | Kevelt ASINDUSTRY | 5 | Jan 24, 2017 | clinicaltrials |
| NCT03005015 | Lenvatinib in Second Line Endometrial Carcinoma | withdrawn | Phase 2 | 0 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 1 | Dec 29, 2016 | clinicaltrials |
| NCT02990728 | Mirena® ± Metformin as Fertility-preserving Treatment for Young Asian Women With Early Endometrial Cancer | unknown | Phase 2 | 120 | Chang Gung Memorial HospitalOTHER | 0 | Dec 13, 2016 | clinicaltrials |
| NCT00031629 | Combination Chemotherapy and Filgrastim or Pegfilgrastim in Treating Patients With Recurrent or Persistent Cancer of the Uterus | completed | Phase 2 | 51 | Gynecologic Oncology GroupNETWORK | 1 | Dec 8, 2016 | clinicaltrials |
| NCT02150213 | Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492 | completed | Phase 2 | 59 | Novartis PharmaceuticalsINDUSTRY | 6 | Dec 5, 2016 | clinicaltrials |
| NCT00171808 | Letrozole in the Treatment of Advanced or Recurrent Hormone Receptor Positive Endometrial Cancer(deFEND) | completed | Phase 2 | 26 | Novartis PharmaceuticalsINDUSTRY | 1 | Nov 18, 2016 | clinicaltrials |
| NCT01061606 | Temsirolimus in Treating Patients With Recurrent or Persistent Cancer of the Uterus | terminated | Phase 2 | 8 | National Cancer Institute (NCI)NIH | 1 | Nov 9, 2016 | clinicaltrials |
| NCT02017353 | Effect of Curcumin Addition to Standard Treatment on Tumour-induced Inflammation in Endometrial Carcinoma | completed | Phase 2 | 7 | University Hospital, GasthuisbergOTHER | 1 | Oct 25, 2016 | clinicaltrials |
| NCT02560571 | Pre-operative Studies for Prediction of Lymph Nodes Involvement in Endometrial Cancer Patients | unknown | Phase 2 | 200 | Meir Medical CenterOTHER | 1 | Sep 20, 2016 | clinicaltrials |
| NCT02042495 | Endometrial Cancer Biomarker Changes Following Exposure to Metformin | withdrawn | Phase 2 | 0 | Jewish General HospitalOTHER | 1 | Aug 30, 2016 | clinicaltrials |
| NCT01455493 | A Study of GDC-0980 in the Treatment of Recurrent or Persistent Endometrial Carcinoma | completed | Phase 2 | 56 | Genentech, Inc.INDUSTRY | 1 | Aug 11, 2016 | clinicaltrials |
| NCT01013324 | Study of XL147 (SAR245408) in Advanced or Recurrent Endometrial Carcinoma | completed | Phase 2 | 67 | SanofiINDUSTRY | 2 | Jun 3, 2016 | clinicaltrials |
| NCT00671606 | Hysteroscopic Lymphatic Mapping for Endometrial Cancer | terminated | Phase 2 | 5 | M.D. Anderson Cancer CenterOTHER | 1 | May 27, 2016 | clinicaltrials |
| NCT00064025 | Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus | completed | Phase 2 | 75 | Gynecologic Oncology GroupNETWORK | 1 | Apr 11, 2016 | clinicaltrials |
| NCT00003334 | Combination Chemotherapy in Treating Patients With Endometrial Cancer, Fallopian Tube Cancer, or Sarcoma of the Female Reproductive Tract | completed | Phase 2 | — | NYU Langone HealthOTHER | 1 | Mar 11, 2016 | clinicaltrials |
| NCT01460979 | Efficacy,Tolerability,Safety of Temsirolimus in Women With Platinum-refractory Ovarian Carcinoma or Advanced Endometrial Carcinoma | completed | Phase 2 | 47 | AGO Study GroupOTHER | 1 | Feb 29, 2016 | clinicaltrials |
| NCT00474994 | Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas | completed | Phase 2 | 53 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 20, 2016 | clinicaltrials |
| NCT00390234 | Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma | completed | Phase 2 | 63 | National Cancer Institute (NCI)NIH | 2 | Dec 7, 2015 | clinicaltrials |
| NCT00238121 | Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer | completed | Phase 2 | 56 | National Cancer Institute (NCI)NIH | 2 | Nov 20, 2015 | clinicaltrials |
| NCT00057863 | Oxaliplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Cervical Cancer | completed | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Nov 17, 2015 | clinicaltrials |
| NCT02042885 | A Clinical Trial to Determine the Most Suitable Dose of OPB-111001 in Patients With Advanced Cancer | terminated | Phase 1 / Phase 2 | 79 | Otsuka Novel Products GmbHINDUSTRY | 1 | Oct 20, 2015 | clinicaltrials |
| NCT01026792 | Temsirolimus in Treating Patients With Cervical Cancer That Is Recurrent, Locally Advanced, Metastatic, or Cannot Be Removed By Surgery | completed | Phase 2 | 38 | National Cancer Institute (NCI)NIH | 1 | Sep 10, 2015 | clinicaltrials |
| NCT00739830 | Clinical Trial of Ridaforolimus Compared to Progestin or Chemotherapy for Advanced Endometrial Carcinoma (MK-8669-007 AM6) | completed | Phase 2 | 130 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jul 1, 2015 | clinicaltrials |
| NCT00217633 | Pelvic Exenteration in Treating Patients With Recurrent Cervical Cancer | completed | Phase 2 | 38 | Gynecologic Oncology GroupNETWORK | 2 | May 29, 2015 | clinicaltrials |
| NCT01379534 | A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer | completed | Phase 2 | 53 | Novartis PharmaceuticalsINDUSTRY | 7 | May 20, 2015 | clinicaltrials |
| NCT02188550 | Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer | unknown | Phase 2 | 20 | Sinai Hospital of BaltimoreOTHER | 1 | May 19, 2015 | clinicaltrials |
| NCT00072176 | Temsirolimus in Treating Patients With Metastatic or Locally Advanced Recurrent Endometrial Cancer | completed | Phase 2 | 62 | National Cancer Institute (NCI)NIH | 1 | Feb 23, 2015 | clinicaltrials |
| NCT00122343 | AP23573 in Female Adult Patients With Recurrent or Persistent Endometrial Cancer (8669-019)(COMPLETED) | completed | Phase 2 | 45 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Feb 19, 2015 | clinicaltrials |
| NCT00389974 | Sunitinib Malate in Treating Patients With Uterine Cervical Cancer That is Stage IVB, Recurrent, or Cannot Be Removed By Surgery | completed | Phase 2 | 19 | National Cancer Institute (NCI)NIH | 1 | Feb 16, 2015 | clinicaltrials |
| NCT00507741 | Study of Vintafolide (MK-8109, EC145) in Participants With Advanced Ovarian and Endometrial Cancers (MK-8109-007, EC-FV-02) | completed | Phase 2 | 49 | EndocyteINDUSTRY | 0 | Jan 7, 2015 | clinicaltrials |
| NCT00388154 | Gemcitabine and Cisplatin for Advanced or Recurrent Endometrial Cancer | completed | Phase 2 | 21 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 13, 2014 | clinicaltrials |
| NCT00870337 | Everolimus in Treating Patients With Relapsed or Metastatic Endometrial Cancer(ENDORAD) | completed | Phase 2 | 44 | ARCAGY/ GINECO GROUPOTHER | 1 | Oct 29, 2014 | clinicaltrials |
| NCT00886873 | Mifepristone 10 or 5 mg for 6 Months to Treat Uterine Fibroids(Mifemyo_2) | completed | Phase 2 / Phase 3 | 100 | Mediterranea Medica S. L.OTHER | 1 | Oct 17, 2014 | clinicaltrials |
| NCT01943058 | Megestrol Acetate or Levonorgestrel-Releasing Intrauterine System in Treating Patients With Atypical Endometrial Hyperplasia or Endometrial Cancer | withdrawn | Phase 2 | 0 | University of Southern CaliforniaOTHER | 0 | Sep 10, 2014 | clinicaltrials |
| NCT01786226 | Mifepristone to Treat Uterine Fibroids | terminated | Phase 2 / Phase 3 | 220 | Mediterranea Medica S. L.OTHER | 1 | Sep 5, 2014 | clinicaltrials |
| NCT01451424 | Evaluation of Safety, Pharmacokinetics, and Efficacy of Proellex Administered Vaginally in Women With Uterine Fibroids | completed | Phase 2 | 40 | Repros Therapeutics Inc.INDUSTRY | 1 | Aug 29, 2014 | clinicaltrials |
| NCT00958893 | An Extension Study Evaluating Safety and Efficacy of Proellex® In Women Who Have Previously Completed ZPU 003 Ext | terminated | Phase 2 | 4 | Repros Therapeutics Inc.INDUSTRY | 1 | Aug 25, 2014 | clinicaltrials |
Data updated 22 days agoSource updated Dec 28, 2017source: clinicaltrials